Yağ Asidi Oksidasyon Bozuklukları

Houten SM, Violante S, Ventura FV, Wanders RJA. The biochemistry and physiology of mitochondrial fatty acid β-oxidation and its genetic di- sorders. Annu Rev Physiol. 2016;78:23-44. doi: 10.1146/annurev-physi- ol-021115-105045.

Merritt JL II, Norris M, Kanungo S. Fatty acid oxidation disorders. Ann Transl Med. 2018;6(24):473. doi: 10.21037/atm.2018.10.57.

Clinical manifestations and management of fatty acid oxidation disorders. Rev Endocr Metab Disord. 2020. PMID: 32654032. 2020 Dec;21(4):479- 493. doi: 10.1007/s11154-020-09568-3.).

Inborn errors of mitochondrial fatty acid oxidation: overview from a clinical perspective. J Lipid Atheroscler. 2021;10(1):1-7. doi: 10.12997/ jla.2021.10.1.1.

Baker JJ, Burton BK. Diagnosis and clinical management of long-chain fatty-acid oxidation disorders: a review. touchREV Endocrinol. 2021;17(2):108-111. doi:10.17925/EE.2021.17.2.108.).

Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty acid β-oxidation. J Inherit Metab Dis. 2010;33(5):469- 477. doi: 10.1007/s10545-010-9061-2.).

Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency / Trifunctio- nal Protein Deficiency. GeneReviews®. Seattle (WA) 1993-2026.: PMID: 36063482 NCBI Bookshelf.: NBK583531 University of Washington, Seatt- le..URL: https://www.ncbi.nlm.nih.gov/books/

Vieira Neto E, et al. Mitochondrial bioenergetics and cardiolipin remode- ling abnormalities in mitochondrial trifunctional protein deficiency. JCI Insight. 2024. PubMed PMID: 39088276.

Wanders RJA, et al. Mitochondrial fatty acid oxidation disorders: labo- ratory diagnosis, pathogenesis, and the complicated route to treatment. 2020. J Lipid Atheroscler. 2020 Sep;9(3):313-333 https://doi.org/10.12997/ jla.2020.9.3.313 pISSN 2287-2892·eISSN 2288-2561

Fletcher AL, Pennesi ME, Harding CO, Weleber RG, Gillingham MB. Ob- servations regarding retinopathy in mitochondrial trifunctional protein deficiencies. Mol Genet Metab. 2012. PubMed PMID: 22459206.

Morris AAM, Spiekerkoetter U. Disorders of Mitochondrial Fatty Acid Oxidation & Riboflavin Metabolism. In: Saudubray JM, Baumgartner MR, García-Cazorla Á, Walter J, editors. Inborn Metabolic Diseases: Diagnosis and Treatment. 7th ed. Berlin, Heidelberg: Springer; 2022. p. 287–301. doi: 10.1007/978-3-662-63123-2_12

Nolfi-Donegan D, Braganza A, Shiva S. Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of me- asurement. Redox Biol. 2020;37:101674. doi: 10.1016/j.redox.2020.101674]

Spiekerkoetter U, Vockley J. Mitochondrial Fatty Acid Oxidation Disor- ders. In: Blau N, Dionisi-Vici C, Ferreira CR, Vianey-Saban C, van Karne- beek CDM, editors. Department of General Pediatrics, University Child- ren’s Hospital, Moorenstr. 5, 40225, Duesseldorf, Germany.

Physician’s Guide to the Diagnosis, Treatment, and Follow-Up of Inheri- ted Metabolic Diseases. 2nd ed. Cham: Springer; 2022. p. 929–957. doi: 10.1007/978-3-030-67727-5_48

Wanders RJA, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta. 2006;1763(12):1707- 1720. doi: 10.1016/j.bbamcr.2006.08.010

Wanders RJA, Waterham HR. Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. Clin Genet. 2005;67(2):107- 133. doi: 10.1111/j.1399-0004.2004.00329.x

Wanders RJA, Komen JC. Peroxisomes, Refsum’s disease and the alpha- and omega-oxidation of phytanic acid. Biochem Soc Trans. 2007;35(Pt 5):865-869. doi: 10.1042/BST0350865

Wierzbicki AS. Peroxisomal disorders affecting phytanic acid alpha-oxi- dation: a review. Biochem Soc Trans. 2007;35(Pt 5):881-886. doi: 10.1042/ BST0350881

Wierzbicki AS. Refsum’s disease: a peroxisomal disorder affecting ph- ytanic acid alpha-oxidation. J Neurochem. 2002;80(5):727-735. doi: 10.1046/j.0022-3042.2002.00766.x

Lindner M, Hoffmann GF, Matern D. Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert me- eting. J Inherit Metab Dis. 2010;33(5):521-526. doi: 10.1007/s10545-010- 9076-8

Marsden D, Bedrosian CL, Vockley J. Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders. Genet Med. 2021;23(5):816-829. doi: 10.1038/s41436-020-01070-0.

Grosse SD, Khoury MJ, Greene CL, Crider KS, Pollitt RJ. The epidemiology of medium chain acyl-CoA dehydrogenase deficiency: an update. Genet Med. 2006;8(4):205-212. doi: 10.1097/01.gim.0000204472.25153.8d.

Chang IJ, Lam C, Vockley J. Medium-Chain Acyl-Coenzyme A Dehyd- rogenase Deficiency. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2026. Updated Sep- tember 26, 2024. Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Inborn errors of mitochondrial fatty acid oxidation: overview from a clinical perspective. J Lipid Atheroscler. 2021;10(1):1-7. doi: 10.12997/ jla.2021.10.1.1.

Institutional experience of newborn screening for inborn metabolism disorders by tandem MS in the Turkish population. PubMed PMID: 32469332. DOI: 10.1515/jpem-2019-0571

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standar- ds and guidelines for the interpretation of sequence variants: a joint con- sensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424. doi: 10.1038/gim.2015.30.

Houten SM, et al. Long-chain acylcarnitines and cardiac excitation-cont- raction coupling: links to arrhythmias. Front Physiol. 2020. 2020 Sep 11:11:577856. doi: 10.3389/fphys.2020.577856. eCollection 2020.

Grünert SC, et al. International guideline on the diagnosis, treatment, and monitoring of long-chain fatty acid oxidation disorders (LC-FAOD). J In- herit Metab Dis. 2026;49(5): e70251. doi: 10.1002/jimd.70251.

Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, Boehles H, et al. Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis. 2009;32(4):498-505. doi: 10.1007/s10545-009-1126-8. Epub 2009 Apr 28. doi: 10.1007/s10545-009-1126-8.

Herrema H, Derks TG, van Dijk TH et al (2008) Disturbed hepatic car- bohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)- deficient mice. Hepatology 47:1894– 1904.

Ventura FV, Ruiter JP, Ijlst L, de Almeida IT, Wanders RJ (1998) Lactic aci- dosis in long-chain fatty acid beta-oxidation disorders. J Inherit Metab Dis 21:645–654. PMID: 9762600DOI: 10.1023/a:1005480516801

Olsen RK, Olpin SE, Andresen BS et al (2007) ETFDH mutations as a major cause of riboflavin-responsive multiple acyl-CoA dehydrogenation deficiency. Brain 130:2045–2054 https://doi.org/10.1093/brain/awm135].

Eric S. Goetzman et. Al. Acyl-CoA dehydrogenase deficiency as a cause of pulmonary surfactant dysfunction. J Biol Chem 289:10668–10679 DOI 10.1074/jbc.M113.540260.

Gillingham MB, Scott B, Elliott D, Harding CO. Metabolic control during exercise with and without medium-chain triglycerides (MCT) in children with long-chain 3-hydroxy acyl-CoA dehydrogenase (LCHAD) or trifun- ctional protein (TFP) deficiency. Mol Genet Metab. 2006;89(1–2):58–63. https://doi.org/10.1016/j.ymgme.2006.06.004

Gillingham MB, Heitner SB, Martin J, Rose S, Goldstein A, El-Gharbawy AH, et al. Triheptanoin versus trioctanoin for long-chain fatty acid oxi- dation disorders: a double blinded, randomized controlled trial. J Inherit Metab Dis. 2017;40(6):831-843. doi: 10.1007/s10545-017-0085-8.

Vockley J, Burton B, Berry GT, Longo N, Phillips J, Sanchez-Valle A, et al. Results from a 78-week, single-arm, open-label phase 2 study to evalua- te UX007 in pediatric and adult patients with severe long-chain fatty acid oxidation disorders. J Inherit Metab Dis. 2019;42(1):169-177. doi: 10.1002/ jimd.12038.

Stanley CA, DeLeeuw S, Coates PM, Vianey-Liaud C, Divry P, Bonnefont JP, Saudubray JM, Haymond M, Trefz FK, Breningstall GN, et al. Chronic cardiomyopathy and weakness or acute coma in children with a defect in carnitine uptake. Ann Neurol. 1991;30(5):709–16. https://doi.org/10.1002/ ana.410300512

Primassin et al. Carnitine Supplementation Induces Acylcarnitine Produ- ction in Tissues of Very Long-Chain Acyl-CoA Dehydrogenase-Deficient Mice, Without Replenishing Low Free Carnitine Pediatric Research volume 63, pages632–637. 2008).

Wilcken B. Fatty acid oxidation disorders: outcome and long-term prog- nosis. J Inherit Metab Dis. 2010;33(5):501-506. doi: 10.1007/s10545-009- 9001-1.

Impact of newborn screening for fatty acid oxidation disorders on neuro- logical outcome: a Belgian retrospective and multicentric study. Eur J Pae- diatr Neurol. 2024. doi: 10.1016/j.ejpn.2024.02.003.

Mütze U, et al. Neurological outcome in long-chain hydroxy fatty acid oxidation disorders. Ann Clin Transl Neurol. 2024;11(4):883-898. doi: 10.1002/acn3.52002.

Grünert SC, Bhattacharya K, Karall D, Langeveld M, Rohr F, Visser G, et al. International guideline on the diagnosis, treatment, and monitoring of long-chain fatty acid oxidation disorders (LC-FAOD). J Inherit Metab Dis. 2026;49(5): e70251. doi: 10.1002/jimd.70251.

El-Hattab AW, Almannai M. Primary Carnitine Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–. Updated 2024 Dec 5. Available from: Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Lee K, Pritchard A, Ahmad A. Carnitine Palmitoyltransferase 1A Deficien- cy. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Inter- net]. Seattle (WA): University of Washington, Seattle; 1993–. Updated 2025 Feb 20. Available from: NCBI Bookshelf URL: https://www.ncbi.nlm.nih. gov/books/

Carnitine-Acylcarnitine Translocase Deficiency. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. Available from: NCBI Bo- okshelf URL: https://www.ncbi.nlm.nih.gov/books/

LoPiccolo MK, Vockley J. Carnitine Palmitoyltransferase II Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Se- attle (WA): University of Washington, Seattle; 1993–. Updated 2026 Apr 9. Available from: NCBI Bookshelf.

American College of Medical Genetics and Genomics. Newborn Screening ACT Sheets and Algorithms [Internet]. Bethesda (MD): ACMG; 2022. PMID: 21938795 Bookshelf ID: NBK55832 Available from: ACMG ACT Sheets and Algorithms.

[Wolfe L, Jethva R, Oglesbee D, Vockley J. Short-Chain Acyl-CoA Dehyd- rogenase Deficiency. In: Adam MP, et al., editors. GeneReviews®. Seattle (WA): University of Washington, Seattle; 2011. Updated 2025 Sep 11. htt- ps://www.ncbi.nlm.nih.gov/books/ PMID: 21938826

[Gallant NM, et al. Biochemical, molecular, and clinical characteristics of children with short chain acyl-CoA dehydrogenase deficiency detected by newborn screening in California. Mol Genet Metab. 2012. PubMed. htt- ps://doi.org/10.1016/j.ymgme.2012.02.007]

[American College of Medical Genetics and Genomics. Newborn Scre- ening ACT Sheets and Algorithms [Internet]. Bethesda (MD): ACMG; 2022. PMID: 21938795 Bookshelf ID: NBK55832 Available from: ACMG ACT Sheets and Algorithms.

Chang IJ, Lam C, Vockley J. Medium-Chain Acyl-Coenzyme A Dehyd- rogenase Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. Ge- neReviews®. Seattle (WA): University of Washington, Seattle; 2000. Upda- ted September 26, 2024. Bookshelf URL: https://www.ncbi.nlm.nih.gov/ books/

American College of Medical Genetics and Genomics. Newborn Screening ACT Sheets and Algorithms [Internet]. Bethesda (MD): ACMG; 2022. PMID: 21938795 Bookshelf ID: NBK55832 Available from: ACMG ACT Sheets and Algorithms.

Chang IJ, Lam C, Vockley J. Medium-Chain Acyl-CoA Dehydrogenase Deficiency: Acute Inpatient Treatment. GeneReviews®, Table 6. PMID: 20301597 Akut tedavi tablosu.

Prasun P, et al. Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency/ Trifunctional Protein Deficiency. GeneReviews 2022. PMID: 36063482 Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

Kılıç A, Tümer L. Uzun zincirli 3-hidroksiaçil-KoA dehidrogenaz eksikliği ve üç işlevli protein eksikliğinde yönetim stratejileri. İçinde: Eminoğlu FT, editör. Mitokondriyal Yağ Asidi Oksidasyon Defektleri, Güncel Gelişmeler ve Potansiyel Tedavi Yaklaşımları. Ankara: Türkiye Klinikleri; 2022. s.13–18. Makale.

Ibdah JA, et al. Inherited long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency and a fetal-maternal interaction cause maternal liver disease and other pregnancy complications. PubMed. 10.1016/S0146-0005(99)80044-5

U.S. Food and Drug Administration. Triheptanoin (Dojolvi), regulatory approval and indication. 2020. Drugs (2020) 80:1595–1600 https://doi. org/10.1007/s40265-020-01399-5

Leslie ND, Saenz-Ayala S. Very Long-Chain Acyl-Coenzyme A Dehyd- rogenase Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. Ge- neReviews®. Seattle (WA): University of Washington, Seattle; 2009. Upda- ted 2025 Aug 7 Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/

American College of Medical Genetics and Genomics. Newborn Screening ACT Sheets and Algorithms [Internet]. Bethesda (MD): ACMG; 2022. PMID: 21938795 Bookshelf ID: NBK55832 Available from: ACMG ACT Sheets and Algorithms.

Van Calcar SC, Sowa M, Rohr F, et al. Nutrition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): An evidence- and consensus-based approach. Mol Genet Metab. 2020;131(1– 2):23–37. PubMed’de makale.

Çok Uzun Zincirli Açil-KoA Dehidrogenaz Eksikliğinde Güncel Yaklaşımlar. Türkiye Klinikleri, 2022. p.19-24.

Prasun P. Multiple Acyl-CoA Dehydrogenase Deficiency. In: Adam MP, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washing- ton, Seattle; 1993–. 2020 Jun 18. PMID: 32550677. Bookshelf URL: https:// www.ncbi.nlm.nih.gov/books/

Goodman SI, McCabe ERB, Fennessey PV, Mace JW. Multiple acyl-CoA dehydrogenase deficiency (glutaric aciduria type II) with transient hyper- sarcosinemia and sarcosinuria; possible inherited deficiency of an electron transfer flavoprotein. Pediatr Res. 1980;14(1):12-17. doi:10.1203/00006450- 198001000-00004.

Goodman SI, Frerman FE. Glutaric acidaemia type II (multiple acyl-CoA dehydrogenation deficiency). J Inherit Metab Dis. 1984;7 Suppl 1:33-37. doi:10.1007/BF03047371.

Electron transfer flavoprotein and its role in mitochondrial energy metabo- lism in health and disease. Gene. 2021. 10.1016/j.gene.2021.145407

Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. 2014. Grünert Orphanet Journal of Rare Di- seases 2014, 9:117 doi:10.1186/s13023-014-0117-5. http://www.ojrd.com/ content/9/1/117.

Screening of multiple acyl-CoA dehydrogenase deficiency in newborns and follow-up of patients. 2021 年 8 月 JOURNAL OF ZHEJIANG UNI- VERSITY（MEDICAL SCIENCE） August 2021 http://www.zjujournals. com/med DOI:10.3724/zdxbyxb-2021-0261.

Newborn screening for fatty acid oxidation disorders in a southern Chine- se population. 2024. PMID: 38187300. PubMed. 2023 Dec 13;10(1):e23671. doi: 10.1016/j.heliyon.2023.e23671. eCollection 2024 Jan 15.

Başak Tezel ve ark. The Development and Organization of Newborn Sc- reening Programs in Turkey. 2014 Jan;28(1):63-9.doi: 10.1002/jcla.21645. Epub 2013 Dec 27. https://doi.org/10.1002/jcla.21645

Disorders of flavin adenine dinucleotide metabolism: MADD and re- lated deficiencies. 2021. PMID: 33279678. PubMed. 10.1016/j.bio- cel.2020.105899

ETF dehydrogenase advances in molecular genetics and impact on tre- atment. 2021. PMID: 33823724. PubMed. 2021 Aug;56(4):360-372. doi: 10.1080/10409238.2021.1908952. Epub 2021 Apr 7.

Olsen RKJ, et al. Riboflavin-responsive and -non-responsive mutations in FAD synthase cause multiple acyl-CoA dehydrogenase and combined respiratory-chain deficiency. Am J Hum Genet. 2016;98(6):1130-1145. do- i:10.1016/j.ajhg.2016.04.006. PMID: 27259049. PubMed.

Signe Mosegaard et al.Riboflavin deficiency—implications for gene- ral human health and inborn errors of metabolism. 2020. 2020 May 28;21(11):3847. doi: 10.3390/ijms21113847.

Grünert SC. Clinical and genetical heterogeneity of late-onset multiple acyl-coenzyme A dehydrogenase deficiency. Orphanet J Rare Dis. 2014;9:117. doi:10.1186/s13023-014-0117-5. http://www.ojrd.com/con- tent/9/1/117.

Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of la- te-onset treatable metabolic disease. Rev Neurol (Paris). 2016;172(3):231- 241. doi:10.1016/j.neurol.2015.11.008. PMID: 27038534. PubMed.

Diagnostic Challenges in Late Onset Multiple Acyl-CoA Dehydrogenase Deficiency: Clinical, Morphological, and Genetic Aspects. 2022. PMID: 35309592. PubMed. 2022 Mar 3:13:815523. doi: 10.3389/fneur.2022.815523. eCollection 2022.

American College of Medical Genetics and Genomics. Newborn Screening ACT Sheets and Algorithms [Internet]. Bethesda (MD): ACMG; 2022. PMID: 21938795 Bookshelf ID: NBK55832 Available from: ACMG ACT Sheets and Algorithms.

Short-Chain Acyl-CoA Dehydrogenase Deficiency. In: GeneReviews® [In- ternet]. Seattle (WA): University of Washington, Seattle. PMID: 21938826 Bookshelf ID: NBK63582 Bookshelf URL: https://www.ncbi.nlm.nih.gov/ books/

American College of Medical Genetics and Genomics. Laboratory analysis of acylcarnitines, 2020 update: a technical standard of the American Colle- ge of Medical Genetics and Genomics (ACMG). Genet Med. 2020. PMID: 33071282 DOI: 10.1038/s41436-020-00990-1

Bilginer Gürbüz B. Nadir görülen bir yağ asidi oksidasyon defekti: 3-hid- roksiaçil-KoA dehidrogenaz eksikliği. İçinde: Eminoğlu FT, editör. Mito- kondriyal Yağ Asidi Oksidasyon Defektleri, Güncel Gelişmeler ve Potansi- yel Tedavi Yaklaşımları. 1. baskı. Ankara: Türkiye Klinikleri; 2022. s.34-37.

Zhang W, Sang YM. Genetic pathogenesis, diagnosis, and treatment of short-chain 3-hydroxyacyl-coenzyme A dehydrogenase hyperinsulinism. Orphanet J Rare Dis. 2021;16(1):467. doi:10.1186/s13023-021-02088-6. PubMed.

Eaton S, Chatziandreou I, Krywawych S, Pen S, Clayton PT, Hussain K. Short-chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with hyperinsulinism: a novel glucose-fatty acid cycle? Biochem Soc Trans. 2003;31(Pt 6):1137-1139. doi:10.1042/BST0311137. PubMed.

Gillis D. Nonsyndromic Genetic Hyperinsulinism Overview. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–. Updated 2024 Oct 31. Bookshelf URL: https://www.ncbi.nlm.nih.gov/books/.

Peña-Quintana L, Correcher-Medina P. Nutritional management of pa- tients with fatty acid oxidation disorders. Nutrients. 2024;16(16):2707. doi:10.3390/nu16162707.

Van Calcar SC, Sowa M, Rohr F, Beazer J, Setlock T, Weihe TU, et al. Nut- rition management guideline for very-long chain acyl-CoA dehydrogenase deficiency (VLCAD): an evidence- and consensus-based approach. Mol Genet Metab. 2020;131(1-2):23-37. doi:10.1016/j.ymgme.2020.10.001. Pu- bMed.

Southeast Regional Genetics Network, Genetic Metabolic Dietitians Inter- national. VLCAD nutrition management guidelines [Internet]. Version 1.4. Updated 2022. Available from: Beslenme kılavuzu.

Long-Chain Hydroxyacyl-CoA Dehydrogenase Deficiency / Trifunctional Protein Deficiency. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. PMID: 36063482 Bookshelf ID: NBK583531 Avai- lable from: GeneReviews.

Porta F, Maiorana A, Gragnaniello V, Procopio E, Gasperini S, Taurisano R, et al. Triheptanoin in patients with long-chain fatty acid oxidation disor- ders: clinical experience in Italy. Ital J Pediatr. 2024;50(1):204. doi:10.1186/ s13052-024-01782-y. PubMed.

A pharmacological profile of triheptanoin for the treatment of long-chain fatty acid oxidation disorders. Expert Rev Clin Pharmacol. 2025. PubMed . PMID: 40633017

DOI: 10.1080/17512433.2025.2528835

El-Hattab AW, Almannai M. Primary Carnitine Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–. Updated 2024 Dec 5. Available from: NCBI Bookshelf.

Leslie ND, Saenz-Ayala S. Very Long-Chain Acyl-Coenzyme A Dehyd- rogenase Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. Ge- neReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–. Updated 2025 Aug 7. Available from: NCBI Bookshelf.

Grünert SC, et al. International guideline on the diagnosis, treatment, and monitoring of long-chain fatty acid oxidation disorders (LC-FAOD). J In- herit Metab Dis. 2026;49(5):e70251. doi:10.1002/jimd.70251.

Orngreen MC, et al. Bezafibrate in skeletal muscle fatty acid oxidati- on disorders: a randomized clinical trial. Neurology. 2014. doi:10.1212/ WNL.0000000000000118. PubMed.

Synthetic mRNA rescues very long-chain acyl-CoA dehydrogenase defi- ciency in patient fibroblasts and a murine model. 2023. PubMed. https:// doi.org/10.1016/j.ymgme.2022.106982

Prasun P. Multiple Acyl-CoA Dehydrogenase Deficiency. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–. PMID: 32550677 Bookshelf ID: NBK558236 Available from: NCBI Bookshelf.